Digital Biology MarketSize, Share & Industry Analysis, 2026-2034By ComponentBy ApplicationBy TechnologyBy End UserBy Deployment ModeBy Biological Data TypeBy Therapeutic AreaBy Therapeutic ModalityBy Business Model
Full title & scope — all 9 axes with their segments
Digital Biology Market Size, Share & Industry Analysis, By Component (Software and Platforms, Services, Hardware and Instruments, Data and Content), By Application (Drug Discovery, Synthetic Biology, Precision Medicine, Clinical Diagnostics, Agricultural Biotechnology, Industrial Biotechnology), By Technology (Artificial Intelligence and Machine Learning, Computational Biology and Bioinformatics, Multi-Omics Analytics, Digital Twins and Biosimulation, Lab Automation and Robotics, Cloud and High-Performance Computing), By End User (Pharmaceutical Companies, Biotechnology Companies, Academic and Research Institutes, Healthcare Providers, Contract Research Organizations, Agricultural Companies), By Deployment Mode (Cloud-Based, On-Premises, Hybrid), By Biological Data Type (Genomic Data, Proteomic Data, Transcriptomic Data, Metabolomic Data, Imaging and Phenotypic Data, Clinical and Real-World Data), By Therapeutic Area (Oncology, Neurology, Infectious Diseases, Immunology and Inflammation, Rare and Genetic Diseases, Metabolic and Cardiovascular Diseases), By Therapeutic Modality (Small Molecules, Biologics and Antibodies, Cell and Gene Therapies, Nucleic Acid Therapeutics, Vaccines), By Business Model (Software Licensing and Subscription, Platform-as-a-Service, Fee-for-Service and Contract Research, Collaboration and Milestone-Based, Data Licensing), and Regional Forecast, 2026-2034
Last Updated: Nov 3, 2026Format: PDFReport ID: CDI-248841
TOC
Full table of contents for the published report, chapter by chapter.
Full chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
1.1Strategic Imperatives
1.2Definition
1.3Digital Biology Comparison By Segments
Chapter 2.Premium Insights
2.1Top 3 Trends to Watch
2.2Top 3 Strategies Followed by Major Players
2.3Top 3 Predictions by Contrive Datum Insights
2.4Top Investment Pockets
2.4.1Market Attractiveness Analysis, By Component
2.4.2Market Attractiveness Analysis, By Application
2.4.3Market Attractiveness Analysis, By Technology
2.4.4Market Attractiveness Analysis, By End User
2.4.5Market Attractiveness Analysis, By Deployment Mode
2.4.6Market Attractiveness Analysis, By Biological Data Type
2.4.7Market Attractiveness Analysis, By Therapeutic Area
2.4.8Market Attractiveness Analysis, By Therapeutic Modality
2.4.9Market Attractiveness Analysis, By Business Model
2.5Key Market Participants — Intensity Mapping
2.6Insights From Primary Respondents
Chapter 3.Market Definition
Chapter 4.Research Methodology
4.1Research Approach
4.1.1Research Programs / Design
4.1.2Market Size Estimation
4.2Data Sources
4.2.1Secondary Sources
4.2.1.1Preliminary Data Mining
4.2.2Primary Sources
4.2.2.1Statistical Model
4.2.2.2Data Triangulation
4.2.2.3Research Objective
4.3Flow Of Methodology
4.4Top-Down / Bottom-Up Approach
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
6.1Market Focus & Value Proposition
6.1.1Target Customers, Priority Markets, and Core Value Proposition
6.1.2Product Differentiation and Positioning Logic
6.2Commercial Model & Pricing Strategy
6.2.1Pricing Approach and Value Capture
6.2.2Contracting, Bundling, and Monetization Framework
6.3Channels, Sales & Partnerships
6.3.1Direct and Indirect Channel Strategy
6.3.2Sales Execution Model and Strategic Partnerships
6.4Marketing, Launch & Execution Roadmap
6.4.1Marketing and Demand Generation Approach
6.4.2Launch Sequencing and Rollout Plan
6.5Operational Readiness & Governance KPIs
6.5.1Supply Chain and Operational Preparedness
6.5.2Regulatory Considerations, Risks, and Performance Tracking
Chapter 7.Market Trends, Strategy & Dynamics
7.1Trends Overview
7.2Strategic Overview
7.3Market Drivers
7.4Market Restraints
7.5Market Opportunities
7.6Market Challenges
7.7Impact Analysis of Market Dynamics
Chapter 8.Porter's Five Forces
8.1Bargaining Power of Suppliers
8.2Bargaining Power of Buyers
8.3Threat of New Entrants
8.4Threat of Substitutes
8.5Competitive Rivalry
Chapter 9.PESTEL Analysis
9.1Political
9.2Economic
9.3Social
9.4Technological
9.5Environmental
9.6Legal
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
12.1Macro-Economic Factors Overview
12.2Forecast Factors — Relevance and Impact
Chapter 13.Market Cost Analysis
13.1Key Raw Materials Analysis
13.1.1Key Raw Materials
13.1.2Price Trend of Key Raw Materials
13.1.3Key Suppliers of Raw Materials
13.1.4Market Concentration Rate of Raw Materials
13.1.5Raw Materials
13.1.6Labor Cost
Chapter 14.Market Supply-Side Analysis
14.1Raw Materials
14.2Price Trends
14.3Industry Chain
14.4Raw Materials Sourcing
14.5Raw Materials Sources of Major Manufacturers
14.6Downstream Buyers
Chapter 15.Global Digital Biology Market Size & Projections, 2020–2034, Revenue (USD Billion)
15.1Global Digital Biology Market Size — Total
15.2Market Size, by Segment (By Component, By Application, By Technology, By End User, By Deployment Mode, By Biological Data Type, By Therapeutic Area, By Therapeutic Modality, By Business Model)
Chapter 16.Global Digital Biology Market Overview, By Component, 2020–2034, Revenue (USD Billion)
16.1Introduction
16.2Global Digital Biology Market Size, By Component, 2020–2034, Revenue (USD Billion)
16.3Global Digital Biology Market Share, By Component (%)
16.3.1Software and Platforms
16.3.1.1Market Size, By Software and Platforms, 2020–2034, Revenue (USD Billion)
16.3.1.2Software and Platforms Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
16.3.1.3Software and Platforms Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
16.3.1.4Software and Platforms Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
16.3.1.5Software and Platforms Size and Projections, By Deployment Mode, 2020–2034, Revenue (USD Billion)
16.3.1.6Software and Platforms Size and Projections, By Biological Data Type, 2020–2034, Revenue (USD Billion)
16.3.1.7Software and Platforms Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
16.3.1.8Software and Platforms Size and Projections, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
16.3.1.9Software and Platforms Size and Projections, By Business Model, 2020–2034, Revenue (USD Billion)
16.3.2Services
16.3.3Hardware and Instruments
16.3.4Data and Content
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 16.3.1 (Software and Platforms).
Chapter 17.Global Digital Biology Market Overview, By Application, 2020–2034, Revenue (USD Billion)
17.1Introduction
17.2Global Digital Biology Market Size, By Application, 2020–2034, Revenue (USD Billion)
17.3Global Digital Biology Market Share, By Application (%)
17.3.1Drug Discovery
17.3.1.1Market Size, By Drug Discovery, 2020–2034, Revenue (USD Billion)
17.3.1.2Drug Discovery Size and Projections, By Component, 2020–2034, Revenue (USD Billion)
17.3.1.3Drug Discovery Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
17.3.1.4Drug Discovery Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
17.3.1.5Drug Discovery Size and Projections, By Deployment Mode, 2020–2034, Revenue (USD Billion)
17.3.1.6Drug Discovery Size and Projections, By Biological Data Type, 2020–2034, Revenue (USD Billion)
17.3.1.7Drug Discovery Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
17.3.1.8Drug Discovery Size and Projections, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
17.3.1.9Drug Discovery Size and Projections, By Business Model, 2020–2034, Revenue (USD Billion)
17.3.2Synthetic Biology
17.3.3Precision Medicine
17.3.4Clinical Diagnostics
17.3.5Agricultural Biotechnology
17.3.6Industrial Biotechnology
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 17.3.1 (Drug Discovery).
Chapter 18.Global Digital Biology Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
18.1Introduction
18.2Global Digital Biology Market Size, By Technology, 2020–2034, Revenue (USD Billion)
18.3Global Digital Biology Market Share, By Technology (%)
18.3.1Artificial Intelligence and Machine Learning
18.3.1.1Market Size, By Artificial Intelligence and Machine Learning, 2020–2034, Revenue (USD Billion)
18.3.1.2Artificial Intelligence and Machine Learning Size and Projections, By Component, 2020–2034, Revenue (USD Billion)
18.3.1.3Artificial Intelligence and Machine Learning Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
18.3.1.4Artificial Intelligence and Machine Learning Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
18.3.1.5Artificial Intelligence and Machine Learning Size and Projections, By Deployment Mode, 2020–2034, Revenue (USD Billion)
18.3.1.6Artificial Intelligence and Machine Learning Size and Projections, By Biological Data Type, 2020–2034, Revenue (USD Billion)
18.3.1.7Artificial Intelligence and Machine Learning Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
18.3.1.8Artificial Intelligence and Machine Learning Size and Projections, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
18.3.1.9Artificial Intelligence and Machine Learning Size and Projections, By Business Model, 2020–2034, Revenue (USD Billion)
18.3.2Computational Biology and Bioinformatics
18.3.3Multi-Omics Analytics
18.3.4Digital Twins and Biosimulation
18.3.5Lab Automation and Robotics
18.3.6Cloud and High-Performance Computing
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 18.3.1 (Artificial Intelligence and Machine Learning).
Chapter 19.Global Digital Biology Market Overview, By End User, 2020–2034, Revenue (USD Billion)
19.1Introduction
19.2Global Digital Biology Market Size, By End User, 2020–2034, Revenue (USD Billion)
19.3Global Digital Biology Market Share, By End User (%)
19.3.1Pharmaceutical Companies
19.3.1.1Market Size, By Pharmaceutical Companies, 2020–2034, Revenue (USD Billion)
19.3.1.2Pharmaceutical Companies Size and Projections, By Component, 2020–2034, Revenue (USD Billion)
19.3.1.3Pharmaceutical Companies Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
19.3.1.4Pharmaceutical Companies Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
19.3.1.5Pharmaceutical Companies Size and Projections, By Deployment Mode, 2020–2034, Revenue (USD Billion)
19.3.1.6Pharmaceutical Companies Size and Projections, By Biological Data Type, 2020–2034, Revenue (USD Billion)
19.3.1.7Pharmaceutical Companies Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
19.3.1.8Pharmaceutical Companies Size and Projections, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
19.3.1.9Pharmaceutical Companies Size and Projections, By Business Model, 2020–2034, Revenue (USD Billion)
19.3.2Biotechnology Companies
19.3.3Academic and Research Institutes
19.3.4Healthcare Providers
19.3.5Contract Research Organizations
19.3.6Agricultural Companies
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 19.3.1 (Pharmaceutical Companies).
Chapter 20.Global Digital Biology Market Overview, By Deployment Mode, 2020–2034, Revenue (USD Billion)
20.1Introduction
20.2Global Digital Biology Market Size, By Deployment Mode, 2020–2034, Revenue (USD Billion)
20.3Global Digital Biology Market Share, By Deployment Mode (%)
20.3.1Cloud-Based
20.3.1.1Market Size, By Cloud-Based, 2020–2034, Revenue (USD Billion)
20.3.1.2Cloud-Based Size and Projections, By Component, 2020–2034, Revenue (USD Billion)
20.3.1.3Cloud-Based Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
20.3.1.4Cloud-Based Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
20.3.1.5Cloud-Based Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
20.3.1.6Cloud-Based Size and Projections, By Biological Data Type, 2020–2034, Revenue (USD Billion)
20.3.1.7Cloud-Based Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
20.3.1.8Cloud-Based Size and Projections, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
20.3.1.9Cloud-Based Size and Projections, By Business Model, 2020–2034, Revenue (USD Billion)
20.3.2On-Premises
20.3.3Hybrid
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 20.3.1 (Cloud-Based).
Chapter 21.Global Digital Biology Market Overview, By Biological Data Type, 2020–2034, Revenue (USD Billion)
21.1Introduction
21.2Global Digital Biology Market Size, By Biological Data Type, 2020–2034, Revenue (USD Billion)
21.3Global Digital Biology Market Share, By Biological Data Type (%)
21.3.1Genomic Data
21.3.1.1Market Size, By Genomic Data, 2020–2034, Revenue (USD Billion)
21.3.1.2Genomic Data Size and Projections, By Component, 2020–2034, Revenue (USD Billion)
21.3.1.3Genomic Data Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
21.3.1.4Genomic Data Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
21.3.1.5Genomic Data Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
21.3.1.6Genomic Data Size and Projections, By Deployment Mode, 2020–2034, Revenue (USD Billion)
21.3.1.7Genomic Data Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
21.3.1.8Genomic Data Size and Projections, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
21.3.1.9Genomic Data Size and Projections, By Business Model, 2020–2034, Revenue (USD Billion)
21.3.2Proteomic Data
21.3.3Transcriptomic Data
21.3.4Metabolomic Data
21.3.5Imaging and Phenotypic Data
21.3.6Clinical and Real-World Data
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 21.3.1 (Genomic Data).
Chapter 22.Global Digital Biology Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
22.1Introduction
22.2Global Digital Biology Market Size, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
22.3Global Digital Biology Market Share, By Therapeutic Area (%)
22.3.1Oncology
22.3.1.1Market Size, By Oncology, 2020–2034, Revenue (USD Billion)
22.3.1.2Oncology Size and Projections, By Component, 2020–2034, Revenue (USD Billion)
22.3.1.3Oncology Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
22.3.1.4Oncology Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
22.3.1.5Oncology Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
22.3.1.6Oncology Size and Projections, By Deployment Mode, 2020–2034, Revenue (USD Billion)
22.3.1.7Oncology Size and Projections, By Biological Data Type, 2020–2034, Revenue (USD Billion)
22.3.1.8Oncology Size and Projections, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
22.3.1.9Oncology Size and Projections, By Business Model, 2020–2034, Revenue (USD Billion)
22.3.2Neurology
22.3.3Infectious Diseases
22.3.4Immunology and Inflammation
22.3.5Rare and Genetic Diseases
22.3.6Metabolic and Cardiovascular Diseases
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 22.3.1 (Oncology).
Chapter 23.Global Digital Biology Market Overview, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
23.1Introduction
23.2Global Digital Biology Market Size, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
23.3Global Digital Biology Market Share, By Therapeutic Modality (%)
23.3.1Small Molecules
23.3.1.1Market Size, By Small Molecules, 2020–2034, Revenue (USD Billion)
23.3.1.2Small Molecules Size and Projections, By Component, 2020–2034, Revenue (USD Billion)
23.3.1.3Small Molecules Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
23.3.1.4Small Molecules Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
23.3.1.5Small Molecules Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
23.3.1.6Small Molecules Size and Projections, By Deployment Mode, 2020–2034, Revenue (USD Billion)
23.3.1.7Small Molecules Size and Projections, By Biological Data Type, 2020–2034, Revenue (USD Billion)
23.3.1.8Small Molecules Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
23.3.1.9Small Molecules Size and Projections, By Business Model, 2020–2034, Revenue (USD Billion)
23.3.2Biologics and Antibodies
23.3.3Cell and Gene Therapies
23.3.4Nucleic Acid Therapeutics
23.3.5Vaccines
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 23.3.1 (Small Molecules).
Chapter 24.Global Digital Biology Market Overview, By Business Model, 2020–2034, Revenue (USD Billion)
24.1Introduction
24.2Global Digital Biology Market Size, By Business Model, 2020–2034, Revenue (USD Billion)
24.3Global Digital Biology Market Share, By Business Model (%)
24.3.1Software Licensing and Subscription
24.3.1.1Market Size, By Software Licensing and Subscription, 2020–2034, Revenue (USD Billion)
24.3.1.2Software Licensing and Subscription Size and Projections, By Component, 2020–2034, Revenue (USD Billion)
24.3.1.3Software Licensing and Subscription Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
24.3.1.4Software Licensing and Subscription Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
24.3.1.5Software Licensing and Subscription Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
24.3.1.6Software Licensing and Subscription Size and Projections, By Deployment Mode, 2020–2034, Revenue (USD Billion)
24.3.1.7Software Licensing and Subscription Size and Projections, By Biological Data Type, 2020–2034, Revenue (USD Billion)
24.3.1.8Software Licensing and Subscription Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
24.3.1.9Software Licensing and Subscription Size and Projections, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
24.3.2Platform-as-a-Service
24.3.3Fee-for-Service and Contract Research
24.3.4Collaboration and Milestone-Based
24.3.5Data Licensing
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 24.3.1 (Software Licensing and Subscription).
Chapter 25.Global Digital Biology Market Size — Segment Comparison
Chapter 26.Global Digital Biology Geography Overview, 2020–2034, Revenue (USD Billion)
26.1Revenue, By Geography, 2020–2034, Revenue (USD Billion)
26.2Share, By Geography, 2020–2034 (%)
26.3Share, By Geography Analysis, 2025, Market Share and CAGR
26.4Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Chapter 27.North America Digital Biology Market Deep-Dive, 2020–2034, Revenue (USD Billion)
27.1Overview, 2020–2034
27.2Size and Projections, 2020–2034, Revenue (USD Billion)
27.2.1By Component, 2020–2034
27.2.2By Application, 2020–2034
27.2.3By Technology, 2020–2034
27.2.4By End User, 2020–2034
27.2.5By Deployment Mode, 2020–2034
27.2.6By Biological Data Type, 2020–2034
27.2.7By Therapeutic Area, 2020–2034
27.2.8By Therapeutic Modality, 2020–2034
27.2.9By Business Model, 2020–2034
27.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
27.3.1US
27.3.1.1US — Key Country Dynamics
27.3.1.2US — Regulatory Framework
27.3.1.3US — Competitive Scenario
27.3.1.4US — Market Overview, 2020–2034, Revenue (USD Billion)
27.3.1.5US — Market Size and Projections, 2020–2034, Revenue (USD Billion)
27.3.1.6US Market Overview, By Component, 2020–2034, Revenue (USD Billion)
27.3.1.7US Market Overview, By Application, 2020–2034, Revenue (USD Billion)
27.3.1.8US Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
27.3.1.9US Market Overview, By End User, 2020–2034, Revenue (USD Billion)
27.3.1.10US Market Overview, By Deployment Mode, 2020–2034, Revenue (USD Billion)
27.3.1.11US Market Overview, By Biological Data Type, 2020–2034, Revenue (USD Billion)
27.3.1.12US Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
27.3.1.13US Market Overview, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
27.3.1.14US Market Overview, By Business Model, 2020–2034, Revenue (USD Billion)
27.3.2Canada
27.3.3Mexico
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 27.3.1 (US).
Chapter 28.Europe Digital Biology Market Deep-Dive, 2020–2034, Revenue (USD Billion)
28.1Overview, 2020–2034
28.2Size and Projections, 2020–2034, Revenue (USD Billion)
28.2.1By Component, 2020–2034
28.2.2By Application, 2020–2034
28.2.3By Technology, 2020–2034
28.2.4By End User, 2020–2034
28.2.5By Deployment Mode, 2020–2034
28.2.6By Biological Data Type, 2020–2034
28.2.7By Therapeutic Area, 2020–2034
28.2.8By Therapeutic Modality, 2020–2034
28.2.9By Business Model, 2020–2034
28.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
28.3.1Germany
28.3.1.1Germany — Key Country Dynamics
28.3.1.2Germany — Regulatory Framework
28.3.1.3Germany — Competitive Scenario
28.3.1.4Germany — Market Overview, 2020–2034, Revenue (USD Billion)
28.3.1.5Germany — Market Size and Projections, 2020–2034, Revenue (USD Billion)
28.3.1.6Germany Market Overview, By Component, 2020–2034, Revenue (USD Billion)
28.3.1.7Germany Market Overview, By Application, 2020–2034, Revenue (USD Billion)
28.3.1.8Germany Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
28.3.1.9Germany Market Overview, By End User, 2020–2034, Revenue (USD Billion)
28.3.1.10Germany Market Overview, By Deployment Mode, 2020–2034, Revenue (USD Billion)
28.3.1.11Germany Market Overview, By Biological Data Type, 2020–2034, Revenue (USD Billion)
28.3.1.12Germany Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
28.3.1.13Germany Market Overview, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
28.3.1.14Germany Market Overview, By Business Model, 2020–2034, Revenue (USD Billion)
28.3.2France
28.3.3Italy
28.3.4Spain
28.3.5UK
28.3.6Nordic Countries
28.3.7Benelux Union
28.3.8Rest of Europe
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 28.3.1 (Germany).
Chapter 29.Asia Pacific Digital Biology Market Deep-Dive, 2020–2034, Revenue (USD Billion)
29.1Overview, 2020–2034
29.2Size and Projections, 2020–2034, Revenue (USD Billion)
29.2.1By Component, 2020–2034
29.2.2By Application, 2020–2034
29.2.3By Technology, 2020–2034
29.2.4By End User, 2020–2034
29.2.5By Deployment Mode, 2020–2034
29.2.6By Biological Data Type, 2020–2034
29.2.7By Therapeutic Area, 2020–2034
29.2.8By Therapeutic Modality, 2020–2034
29.2.9By Business Model, 2020–2034
29.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
29.3.1India
29.3.1.1India — Key Country Dynamics
29.3.1.2India — Regulatory Framework
29.3.1.3India — Competitive Scenario
29.3.1.4India — Market Overview, 2020–2034, Revenue (USD Billion)
29.3.1.5India — Market Size and Projections, 2020–2034, Revenue (USD Billion)
29.3.1.6India Market Overview, By Component, 2020–2034, Revenue (USD Billion)
29.3.1.7India Market Overview, By Application, 2020–2034, Revenue (USD Billion)
29.3.1.8India Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
29.3.1.9India Market Overview, By End User, 2020–2034, Revenue (USD Billion)
29.3.1.10India Market Overview, By Deployment Mode, 2020–2034, Revenue (USD Billion)
29.3.1.11India Market Overview, By Biological Data Type, 2020–2034, Revenue (USD Billion)
29.3.1.12India Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
29.3.1.13India Market Overview, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
29.3.1.14India Market Overview, By Business Model, 2020–2034, Revenue (USD Billion)
29.3.2Australia
29.3.3China
29.3.4China (Taiwan)
29.3.5Japan
29.3.6South Korea
29.3.7Southeast Asia
29.3.8Indonesia
29.3.9Thailand
29.3.10Malaysia
29.3.11Singapore
29.3.12Rest of Asia Pacific
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 29.3.1 (India).
Chapter 30.Latin America Digital Biology Market Deep-Dive, 2020–2034, Revenue (USD Billion)
30.1Overview, 2020–2034
30.2Size and Projections, 2020–2034, Revenue (USD Billion)
30.2.1By Component, 2020–2034
30.2.2By Application, 2020–2034
30.2.3By Technology, 2020–2034
30.2.4By End User, 2020–2034
30.2.5By Deployment Mode, 2020–2034
30.2.6By Biological Data Type, 2020–2034
30.2.7By Therapeutic Area, 2020–2034
30.2.8By Therapeutic Modality, 2020–2034
30.2.9By Business Model, 2020–2034
30.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
30.3.1Brazil
30.3.1.1Brazil — Key Country Dynamics
30.3.1.2Brazil — Regulatory Framework
30.3.1.3Brazil — Competitive Scenario
30.3.1.4Brazil — Market Overview, 2020–2034, Revenue (USD Billion)
30.3.1.5Brazil — Market Size and Projections, 2020–2034, Revenue (USD Billion)
30.3.1.6Brazil Market Overview, By Component, 2020–2034, Revenue (USD Billion)
30.3.1.7Brazil Market Overview, By Application, 2020–2034, Revenue (USD Billion)
30.3.1.8Brazil Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
30.3.1.9Brazil Market Overview, By End User, 2020–2034, Revenue (USD Billion)
30.3.1.10Brazil Market Overview, By Deployment Mode, 2020–2034, Revenue (USD Billion)
30.3.1.11Brazil Market Overview, By Biological Data Type, 2020–2034, Revenue (USD Billion)
30.3.1.12Brazil Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
30.3.1.13Brazil Market Overview, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
30.3.1.14Brazil Market Overview, By Business Model, 2020–2034, Revenue (USD Billion)
30.3.2Argentina
30.3.3Rest of Latin America
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 30.3.1 (Brazil).
Chapter 31.Middle East and Africa Digital Biology Market Deep-Dive, 2020–2034, Revenue (USD Billion)
31.1Overview, 2020–2034
31.2Size and Projections, 2020–2034, Revenue (USD Billion)
31.2.1By Component, 2020–2034
31.2.2By Application, 2020–2034
31.2.3By Technology, 2020–2034
31.2.4By End User, 2020–2034
31.2.5By Deployment Mode, 2020–2034
31.2.6By Biological Data Type, 2020–2034
31.2.7By Therapeutic Area, 2020–2034
31.2.8By Therapeutic Modality, 2020–2034
31.2.9By Business Model, 2020–2034
31.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
31.3.1GCC
31.3.1.1GCC — Key Country Dynamics
31.3.1.2GCC — Regulatory Framework
31.3.1.3GCC — Competitive Scenario
31.3.1.4GCC — Market Overview, 2020–2034, Revenue (USD Billion)
31.3.1.5GCC — Market Size and Projections, 2020–2034, Revenue (USD Billion)
31.3.1.6GCC Market Overview, By Component, 2020–2034, Revenue (USD Billion)
31.3.1.7GCC Market Overview, By Application, 2020–2034, Revenue (USD Billion)
31.3.1.8GCC Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
31.3.1.9GCC Market Overview, By End User, 2020–2034, Revenue (USD Billion)
31.3.1.10GCC Market Overview, By Deployment Mode, 2020–2034, Revenue (USD Billion)
31.3.1.11GCC Market Overview, By Biological Data Type, 2020–2034, Revenue (USD Billion)
31.3.1.12GCC Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
31.3.1.13GCC Market Overview, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
31.3.1.14GCC Market Overview, By Business Model, 2020–2034, Revenue (USD Billion)
31.3.2Egypt
31.3.3South Africa
31.3.4Rest of the Middle East & Africa
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 31.3.1 (GCC).
Chapter 32.Application / Use-Case Analysis
Chapter 33.Vendor Capability Scorecard
Chapter 34.Scenario Forecasts
34.1Bull-case Trajectory
34.2Base-case Trajectory
34.3Bear-case Trajectory
Chapter 35.Top 10 Key Clients of Top 10 Players
Chapter 36.Top 10 Suppliers
Chapter 37.Competitive Landscape
37.1Thermo Fisher Scientific Inc.
37.2Illumina, Inc.
37.3Schrödinger, Inc.
37.4Certara, Inc.
37.5Dassault Systèmes SE
37.6Insilico Medicine
37.7Recursion Pharmaceuticals, Inc.
37.8Exscientia plc
37.9Benchling, Inc.
37.10Agilent Technologies, Inc.
37.11QIAGEN N.V.
37.12Danaher Corporation
37.13Revvity, Inc.
37.14Twist Bioscience Corporation
37.15Ginkgo Bioworks Holdings, Inc.
37.16Simulations Plus, Inc.
37.17Absci Corporation
37.18Evotec SE
37.19Compugen Ltd.
37.20BenevolentAI
37.21Genedata AG
37.22Bio-Rad Laboratories, Inc.
37.2310x Genomics, Inc.
37.24Pacific Biosciences of California, Inc.
37.25Oxford Nanopore Technologies plc
37.26NVIDIA Corporation
37.27Tempus AI, Inc.
37.28Dotmatics
37.29Cellarity, Inc.
Chapter 38.Partnerships & M&A
Chapter 39.Key Vendor Analysis
39.1Thermo Fisher Scientific Inc.
39.2Illumina, Inc.
39.3Schrödinger, Inc.
39.4Certara, Inc.
39.5Dassault Systèmes SE
39.6Insilico Medicine
39.7Recursion Pharmaceuticals, Inc.
39.8Exscientia plc
39.9Benchling, Inc.
39.10Agilent Technologies, Inc.
39.11QIAGEN N.V.
39.12Danaher Corporation
39.13Revvity, Inc.
39.14Twist Bioscience Corporation
39.15Ginkgo Bioworks Holdings, Inc.
39.16Simulations Plus, Inc.
39.17Absci Corporation
39.18Evotec SE
39.19Compugen Ltd.
39.20BenevolentAI
39.21Genedata AG
39.22Bio-Rad Laboratories, Inc.
39.2310x Genomics, Inc.
39.24Pacific Biosciences of California, Inc.
39.25Oxford Nanopore Technologies plc
39.26NVIDIA Corporation
39.27Tempus AI, Inc.
39.28Dotmatics
39.29Cellarity, Inc.
Chapter 40.Marketing Strategy Analysis, Distributors & Traders
Chapter 41.Outlook of the Market
Chapter 42.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
Figure 2.1Top 3 Trends to Watch
Figure 2.4Top Investment Pockets
Figure 2.4.1Market Attractiveness Analysis, By Component
Figure 2.4.2Market Attractiveness Analysis, By Application
Figure 2.4.3Market Attractiveness Analysis, By Technology
Figure 2.4.4Market Attractiveness Analysis, By End User
Figure 2.4.5Market Attractiveness Analysis, By Deployment Mode
Figure 2.4.6Market Attractiveness Analysis, By Biological Data Type
Figure 2.4.7Market Attractiveness Analysis, By Therapeutic Area
Figure 2.4.8Market Attractiveness Analysis, By Therapeutic Modality
Figure 2.4.9Market Attractiveness Analysis, By Business Model
Figure 2.5Key Market Participants — Intensity Mapping
Figure 4.2.2.2Data Triangulation
Figure 4.3Flow Of Methodology
Figure 4.4Top-Down / Bottom-Up Approach
Figure 6.1.2Product Differentiation and Positioning Logic
Figure 16.3Global Digital Biology Market Share, By Component (%)
Figure 17.3Global Digital Biology Market Share, By Application (%)
Figure 18.3Global Digital Biology Market Share, By Technology (%)
Figure 19.3Global Digital Biology Market Share, By End User (%)
Figure 20.3Global Digital Biology Market Share, By Deployment Mode (%)
Figure 21.3Global Digital Biology Market Share, By Biological Data Type (%)
Figure 22.3Global Digital Biology Market Share, By Therapeutic Area (%)
Figure 23.3Global Digital Biology Market Share, By Therapeutic Modality (%)
Figure 24.3Global Digital Biology Market Share, By Business Model (%)
Figure 26.2Share, By Geography, 2020–2034 (%)
Figure 26.3Share, By Geography Analysis, 2025, Market Share and CAGR
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Table 1.3Digital Biology Comparison By Segments
Table 4.1.2Market Size Estimation
Table 15.1Global Digital Biology Market Size — Total
Table 15.2Market Size, by Segment (By Component, By Application, By Technology, By End User, By Deployment Mode, By Biological Data Type, By Therapeutic Area, By Therapeutic Modality, By Business Model)
Table 16.2Global Digital Biology Market Size, By Component, 2020–2034, Revenue (USD Billion)
Table 16.3.1.1Market Size, By Software and Platforms, 2020–2034, Revenue (USD Billion)
Table 16.3.1.2Software and Platforms Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 16.3.1.3Software and Platforms Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
Table 16.3.1.4Software and Platforms Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 16.3.1.5Software and Platforms Size and Projections, By Deployment Mode, 2020–2034, Revenue (USD Billion)
Table 16.3.1.6Software and Platforms Size and Projections, By Biological Data Type, 2020–2034, Revenue (USD Billion)
Table 16.3.1.7Software and Platforms Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 16.3.1.8Software and Platforms Size and Projections, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
Table 16.3.1.9Software and Platforms Size and Projections, By Business Model, 2020–2034, Revenue (USD Billion)
Table 17.2Global Digital Biology Market Size, By Application, 2020–2034, Revenue (USD Billion)
Table 17.3.1.1Market Size, By Drug Discovery, 2020–2034, Revenue (USD Billion)
Table 17.3.1.2Drug Discovery Size and Projections, By Component, 2020–2034, Revenue (USD Billion)
Table 17.3.1.3Drug Discovery Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
Table 17.3.1.4Drug Discovery Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 17.3.1.5Drug Discovery Size and Projections, By Deployment Mode, 2020–2034, Revenue (USD Billion)
Table 17.3.1.6Drug Discovery Size and Projections, By Biological Data Type, 2020–2034, Revenue (USD Billion)
Table 17.3.1.7Drug Discovery Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 17.3.1.8Drug Discovery Size and Projections, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
Table 17.3.1.9Drug Discovery Size and Projections, By Business Model, 2020–2034, Revenue (USD Billion)
Table 18.2Global Digital Biology Market Size, By Technology, 2020–2034, Revenue (USD Billion)
Table 18.3.1.1Market Size, By Artificial Intelligence and Machine Learning, 2020–2034, Revenue (USD Billion)
Table 18.3.1.2Artificial Intelligence and Machine Learning Size and Projections, By Component, 2020–2034, Revenue (USD Billion)
Table 18.3.1.3Artificial Intelligence and Machine Learning Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 18.3.1.4Artificial Intelligence and Machine Learning Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 18.3.1.5Artificial Intelligence and Machine Learning Size and Projections, By Deployment Mode, 2020–2034, Revenue (USD Billion)
Table 18.3.1.6Artificial Intelligence and Machine Learning Size and Projections, By Biological Data Type, 2020–2034, Revenue (USD Billion)
Table 18.3.1.7Artificial Intelligence and Machine Learning Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 18.3.1.8Artificial Intelligence and Machine Learning Size and Projections, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
Table 18.3.1.9Artificial Intelligence and Machine Learning Size and Projections, By Business Model, 2020–2034, Revenue (USD Billion)
Table 19.2Global Digital Biology Market Size, By End User, 2020–2034, Revenue (USD Billion)
Table 19.3.1.1Market Size, By Pharmaceutical Companies, 2020–2034, Revenue (USD Billion)
Table 19.3.1.2Pharmaceutical Companies Size and Projections, By Component, 2020–2034, Revenue (USD Billion)
Table 19.3.1.3Pharmaceutical Companies Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 19.3.1.4Pharmaceutical Companies Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
Table 19.3.1.5Pharmaceutical Companies Size and Projections, By Deployment Mode, 2020–2034, Revenue (USD Billion)
Table 19.3.1.6Pharmaceutical Companies Size and Projections, By Biological Data Type, 2020–2034, Revenue (USD Billion)
Table 19.3.1.7Pharmaceutical Companies Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 19.3.1.8Pharmaceutical Companies Size and Projections, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
Table 19.3.1.9Pharmaceutical Companies Size and Projections, By Business Model, 2020–2034, Revenue (USD Billion)
Table 20.2Global Digital Biology Market Size, By Deployment Mode, 2020–2034, Revenue (USD Billion)
Table 20.3.1.1Market Size, By Cloud-Based, 2020–2034, Revenue (USD Billion)
Table 20.3.1.2Cloud-Based Size and Projections, By Component, 2020–2034, Revenue (USD Billion)
Table 20.3.1.3Cloud-Based Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 20.3.1.4Cloud-Based Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
Table 20.3.1.5Cloud-Based Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 20.3.1.6Cloud-Based Size and Projections, By Biological Data Type, 2020–2034, Revenue (USD Billion)
Table 20.3.1.7Cloud-Based Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 20.3.1.8Cloud-Based Size and Projections, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
Table 20.3.1.9Cloud-Based Size and Projections, By Business Model, 2020–2034, Revenue (USD Billion)
Table 21.2Global Digital Biology Market Size, By Biological Data Type, 2020–2034, Revenue (USD Billion)
Table 21.3.1.1Market Size, By Genomic Data, 2020–2034, Revenue (USD Billion)
Table 21.3.1.2Genomic Data Size and Projections, By Component, 2020–2034, Revenue (USD Billion)
Table 21.3.1.3Genomic Data Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 21.3.1.4Genomic Data Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
Table 21.3.1.5Genomic Data Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 21.3.1.6Genomic Data Size and Projections, By Deployment Mode, 2020–2034, Revenue (USD Billion)
Table 21.3.1.7Genomic Data Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 21.3.1.8Genomic Data Size and Projections, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
Table 21.3.1.9Genomic Data Size and Projections, By Business Model, 2020–2034, Revenue (USD Billion)
Table 22.2Global Digital Biology Market Size, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 22.3.1.1Market Size, By Oncology, 2020–2034, Revenue (USD Billion)
Table 22.3.1.2Oncology Size and Projections, By Component, 2020–2034, Revenue (USD Billion)
Table 22.3.1.3Oncology Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 22.3.1.4Oncology Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
Table 22.3.1.5Oncology Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 22.3.1.6Oncology Size and Projections, By Deployment Mode, 2020–2034, Revenue (USD Billion)
Table 22.3.1.7Oncology Size and Projections, By Biological Data Type, 2020–2034, Revenue (USD Billion)
Table 22.3.1.8Oncology Size and Projections, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
Table 22.3.1.9Oncology Size and Projections, By Business Model, 2020–2034, Revenue (USD Billion)
Table 23.2Global Digital Biology Market Size, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
Table 23.3.1.1Market Size, By Small Molecules, 2020–2034, Revenue (USD Billion)
Table 23.3.1.2Small Molecules Size and Projections, By Component, 2020–2034, Revenue (USD Billion)
Table 23.3.1.3Small Molecules Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 23.3.1.4Small Molecules Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
Table 23.3.1.5Small Molecules Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 23.3.1.6Small Molecules Size and Projections, By Deployment Mode, 2020–2034, Revenue (USD Billion)
Table 23.3.1.7Small Molecules Size and Projections, By Biological Data Type, 2020–2034, Revenue (USD Billion)
Table 23.3.1.8Small Molecules Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 23.3.1.9Small Molecules Size and Projections, By Business Model, 2020–2034, Revenue (USD Billion)
Table 24.2Global Digital Biology Market Size, By Business Model, 2020–2034, Revenue (USD Billion)
Table 24.3.1.1Market Size, By Software Licensing and Subscription, 2020–2034, Revenue (USD Billion)
Table 24.3.1.2Software Licensing and Subscription Size and Projections, By Component, 2020–2034, Revenue (USD Billion)
Table 24.3.1.3Software Licensing and Subscription Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 24.3.1.4Software Licensing and Subscription Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
Table 24.3.1.5Software Licensing and Subscription Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 24.3.1.6Software Licensing and Subscription Size and Projections, By Deployment Mode, 2020–2034, Revenue (USD Billion)
Table 24.3.1.7Software Licensing and Subscription Size and Projections, By Biological Data Type, 2020–2034, Revenue (USD Billion)
Table 24.3.1.8Software Licensing and Subscription Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 24.3.1.9Software Licensing and Subscription Size and Projections, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
Table 26.1Revenue, By Geography, 2020–2034, Revenue (USD Billion)
Table 26.4Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 27.1Overview, 2020–2034
Table 27.2Size and Projections, 2020–2034, Revenue (USD Billion)
Table 27.2.1By Component, 2020–2034
Table 27.2.2By Application, 2020–2034
Table 27.2.3By Technology, 2020–2034
Table 27.2.4By End User, 2020–2034
Table 27.2.5By Deployment Mode, 2020–2034
Table 27.2.6By Biological Data Type, 2020–2034
Table 27.2.7By Therapeutic Area, 2020–2034
Table 27.2.8By Therapeutic Modality, 2020–2034
Table 27.2.9By Business Model, 2020–2034
Table 27.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 27.3.1.4US — Market Overview, 2020–2034, Revenue (USD Billion)
Table 27.3.1.5US — Market Size and Projections, 2020–2034, Revenue (USD Billion)
Table 27.3.1.6US Market Overview, By Component, 2020–2034, Revenue (USD Billion)
Table 27.3.1.7US Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Table 27.3.1.8US Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
Table 27.3.1.9US Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Table 27.3.1.10US Market Overview, By Deployment Mode, 2020–2034, Revenue (USD Billion)
Table 27.3.1.11US Market Overview, By Biological Data Type, 2020–2034, Revenue (USD Billion)
Table 27.3.1.12US Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 27.3.1.13US Market Overview, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
Table 27.3.1.14US Market Overview, By Business Model, 2020–2034, Revenue (USD Billion)
Table 28.1Overview, 2020–2034
Table 28.2Size and Projections, 2020–2034, Revenue (USD Billion)
Table 28.2.1By Component, 2020–2034
Table 28.2.2By Application, 2020–2034
Table 28.2.3By Technology, 2020–2034
Table 28.2.4By End User, 2020–2034
Table 28.2.5By Deployment Mode, 2020–2034
Table 28.2.6By Biological Data Type, 2020–2034
Table 28.2.7By Therapeutic Area, 2020–2034
Table 28.2.8By Therapeutic Modality, 2020–2034
Table 28.2.9By Business Model, 2020–2034
Table 28.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 28.3.1.4Germany — Market Overview, 2020–2034, Revenue (USD Billion)
Table 28.3.1.5Germany — Market Size and Projections, 2020–2034, Revenue (USD Billion)
Table 28.3.1.6Germany Market Overview, By Component, 2020–2034, Revenue (USD Billion)
Table 28.3.1.7Germany Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Table 28.3.1.8Germany Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
Table 28.3.1.9Germany Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Table 28.3.1.10Germany Market Overview, By Deployment Mode, 2020–2034, Revenue (USD Billion)
Table 28.3.1.11Germany Market Overview, By Biological Data Type, 2020–2034, Revenue (USD Billion)
Table 28.3.1.12Germany Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 28.3.1.13Germany Market Overview, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
Table 28.3.1.14Germany Market Overview, By Business Model, 2020–2034, Revenue (USD Billion)
Table 29.1Overview, 2020–2034
Table 29.2Size and Projections, 2020–2034, Revenue (USD Billion)
Table 29.2.1By Component, 2020–2034
Table 29.2.2By Application, 2020–2034
Table 29.2.3By Technology, 2020–2034
Table 29.2.4By End User, 2020–2034
Table 29.2.5By Deployment Mode, 2020–2034
Table 29.2.6By Biological Data Type, 2020–2034
Table 29.2.7By Therapeutic Area, 2020–2034
Table 29.2.8By Therapeutic Modality, 2020–2034
Table 29.2.9By Business Model, 2020–2034
Table 29.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 29.3.1.4India — Market Overview, 2020–2034, Revenue (USD Billion)
Table 29.3.1.5India — Market Size and Projections, 2020–2034, Revenue (USD Billion)
Table 29.3.1.6India Market Overview, By Component, 2020–2034, Revenue (USD Billion)
Table 29.3.1.7India Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Table 29.3.1.8India Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
Table 29.3.1.9India Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Table 29.3.1.10India Market Overview, By Deployment Mode, 2020–2034, Revenue (USD Billion)
Table 29.3.1.11India Market Overview, By Biological Data Type, 2020–2034, Revenue (USD Billion)
Table 29.3.1.12India Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 29.3.1.13India Market Overview, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
Table 29.3.1.14India Market Overview, By Business Model, 2020–2034, Revenue (USD Billion)
Table 30.1Overview, 2020–2034
Table 30.2Size and Projections, 2020–2034, Revenue (USD Billion)
Table 30.2.1By Component, 2020–2034
Table 30.2.2By Application, 2020–2034
Table 30.2.3By Technology, 2020–2034
Table 30.2.4By End User, 2020–2034
Table 30.2.5By Deployment Mode, 2020–2034
Table 30.2.6By Biological Data Type, 2020–2034
Table 30.2.7By Therapeutic Area, 2020–2034
Table 30.2.8By Therapeutic Modality, 2020–2034
Table 30.2.9By Business Model, 2020–2034
Table 30.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 30.3.1.4Brazil — Market Overview, 2020–2034, Revenue (USD Billion)
Table 30.3.1.5Brazil — Market Size and Projections, 2020–2034, Revenue (USD Billion)
Table 30.3.1.6Brazil Market Overview, By Component, 2020–2034, Revenue (USD Billion)
Table 30.3.1.7Brazil Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Table 30.3.1.8Brazil Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
Table 30.3.1.9Brazil Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Table 30.3.1.10Brazil Market Overview, By Deployment Mode, 2020–2034, Revenue (USD Billion)
Table 30.3.1.11Brazil Market Overview, By Biological Data Type, 2020–2034, Revenue (USD Billion)
Table 30.3.1.12Brazil Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 30.3.1.13Brazil Market Overview, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
Table 30.3.1.14Brazil Market Overview, By Business Model, 2020–2034, Revenue (USD Billion)
Table 31.1Overview, 2020–2034
Table 31.2Size and Projections, 2020–2034, Revenue (USD Billion)
Table 31.2.1By Component, 2020–2034
Table 31.2.2By Application, 2020–2034
Table 31.2.3By Technology, 2020–2034
Table 31.2.4By End User, 2020–2034
Table 31.2.5By Deployment Mode, 2020–2034
Table 31.2.6By Biological Data Type, 2020–2034
Table 31.2.7By Therapeutic Area, 2020–2034
Table 31.2.8By Therapeutic Modality, 2020–2034
Table 31.2.9By Business Model, 2020–2034
Table 31.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 31.3.1.4GCC — Market Overview, 2020–2034, Revenue (USD Billion)
Table 31.3.1.5GCC — Market Size and Projections, 2020–2034, Revenue (USD Billion)
Table 31.3.1.6GCC Market Overview, By Component, 2020–2034, Revenue (USD Billion)
Table 31.3.1.7GCC Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Table 31.3.1.8GCC Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
Table 31.3.1.9GCC Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Table 31.3.1.10GCC Market Overview, By Deployment Mode, 2020–2034, Revenue (USD Billion)
Table 31.3.1.11GCC Market Overview, By Biological Data Type, 2020–2034, Revenue (USD Billion)
Table 31.3.1.12GCC Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 31.3.1.13GCC Market Overview, By Therapeutic Modality, 2020–2034, Revenue (USD Billion)
Table 31.3.1.14GCC Market Overview, By Business Model, 2020–2034, Revenue (USD Billion)
Scope
Questions This Report Answers
6 questions01
What is the market size and growth rate, globally and by region?
02
How is the market segmented, and which segments lead?
03
Which regions and countries are covered, and how do they compare?
04
What are the key drivers, restraints, opportunities and challenges?
05
Who are the leading companies operating in this market?
06
What trends are expected to shape the market through the forecast period?
Questions
Frequently Asked Questions
01What is the Digital Biology Market projected to reach?
USD 44.8 USD Billion by 2034, CAGR 15.65%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 42% of global revenue through 2034.
05Which segment leads the market?
Software and Platforms is the largest line by component, at 38% of revenue in 2025.
06Who are the key companies profiled?
Thermo Fisher Scientific Inc., Illumina, Inc., Schrödinger, Inc., Certara, Inc., Dassault Systèmes SE, Insilico Medicine, Recursion Pharmaceuticals, Inc., Exscientia plc, Benchling, Inc., Agilent Technologies, Inc., QIAGEN N.V., Danaher Corporation, Revvity, Inc., Twist Bioscience Corporation, Ginkgo Bioworks Holdings, Inc., Simulations Plus, Inc., Absci Corporation, Evotec SE, Compugen Ltd., BenevolentAI, Genedata AG, Bio-Rad Laboratories, Inc., 10x Genomics, Inc., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies plc, NVIDIA Corporation, Tempus AI, Inc., Dotmatics, Cellarity, Inc.. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
425+
Dedicated research analysts
1,200+
Reports published
Why CDI
Why choose CDI
Data triangulated across primary and secondary sources
Complimentary analyst call included with every purchase
Custom data cuts and post-purchase support available
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.
Explore
Related Reports
Pharmaceuticals & Biotech
RNA Editing Market
USD 9.25 Bn by 2034, CAGR 19%
Pharmaceuticals & Biotech
Genomics Market
USD 129.88 Bn by 2034, CAGR 12.5%
Pharmaceuticals & Biotech
Next Generation Sequencing Market
USD 49.09 Bn by 2034, CAGR 14.5%
Pharmaceuticals & Biotech
Clinical Trial Supplies Market
USD 10.3 Bn by 2034, CAGR 8.3%
Pharmaceuticals & Biotech
Biologics API Market
USD 138.6 Bn by 2034, CAGR 7.8%
Pharmaceuticals & Biotech
Microfluids Market
USD 111.12 Bn by 2034, CAGR 12.5%